Third Harmonic Bio Overview
- Year Founded
-
2019
- Status
-
Out of Business
- Employees
-
31
- Latest Deal Type
-
Out of Business
Third Harmonic Bio General Information
Description
Developer of an oral KIT inhibitor designed for the treatment of severe allergy and inflammation. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate, THB335, is a potent, selective, oral small molecule KIT inhibitor for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Contact Information
Website
www.thirdharmonicbio.comCorporate Office
- 300 Technology Square
- 8th Floor
- Cambridge, MA 02139
- United States
Corporate Office
- 300 Technology Square
- 8th Floor
- Cambridge, MA 02139
- United States
Third Harmonic Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 30-Jan-2026 | Completed | Out of Business | |||
| 4. IPO | 14-Sep-2022 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 16-Feb-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 01-Nov-2021 | $50M | $50M | Completed | Startup | |
| 1. Seed Round | 01-Jan-2019 | Completed | Startup |
Third Harmonic Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 13,750,000 | $0.000100 | 8% | $1.6 | $1.6 | 1x | $1.6 | 20.29% |
| Series A-1 | 19,970,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 29.47% |
Third Harmonic Bio Comparisons
Industry
Financing
Details
Third Harmonic Bio Competitors (5)
One of Third Harmonic Bio’s 5 competitors is Celcuity, a Formerly VC-backed company based in Minneapolis, MN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Celcuity | Formerly VC-backed | Minneapolis, MN | ||||
| Immunomic Therapeutics | Venture Capital-Backed | Rockville, MD | ||||
| Forte Biosciences | Formerly PE-Backed | Dallas, TX | ||||
| BioVie | Formerly VC-backed | Carson City, NV | ||||
| Cellectis | Formerly VC-backed | Paris, France |
Third Harmonic Bio Patents
Third Harmonic Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025259929-A1 | Compounds and compositions as c-kit kinase inhibitors | Pending | 13-Jun-2024 | ||
| WO-2025256609-A1 | Crystalline forms of a selective c-kit kinase inhibitor | Pending | 13-Jun-2024 | ||
| WO-2024123966-A1 | Compounds and compositions as c-kit kinase inhibitors | Inactive | 07-Dec-2022 | ||
| WO-2024124002-A1 | Compounds and compositions as c-kit kinase inhibitors | Inactive | 07-Dec-2022 | ||
| WO-2022182982-A1 | Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor | Inactive | 26-Feb-2021 | A61K31/437 |
Third Harmonic Bio Signals
Third Harmonic Bio ESG
Risk Overview
Risk Rating
Updated September, 30, 2023
34.1 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
Third Harmonic Bio FAQs
-
When was Third Harmonic Bio founded?
Third Harmonic Bio was founded in 2019.
-
Where is Third Harmonic Bio headquartered?
Third Harmonic Bio is headquartered in Cambridge, MA.
-
What is the size of Third Harmonic Bio?
Third Harmonic Bio has 31 total employees.
-
What industry is Third Harmonic Bio in?
Third Harmonic Bio’s primary industry is Discovery Tools (Healthcare).
-
Is Third Harmonic Bio a private or public company?
Third Harmonic Bio is a Private company.
-
What is Third Harmonic Bio’s current revenue?
The current revenue for Third Harmonic Bio is .
-
How much funding has Third Harmonic Bio raised over time?
Third Harmonic Bio has raised $340M.
-
Who are Third Harmonic Bio’s competitors?
Celcuity, Immunomic Therapeutics, Forte Biosciences, BioVie, and Cellectis are competitors of Third Harmonic Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process